The Asia Pacific peptide therapeutics CDMO market size was estimated at USD 1.03 million in 2025 and is projected to be worth around USD 2,349.56 million by 2035, expanding at a CAGR of 12.40% from 2026 to 2035. Growing due to cost-effective manufacturing services and rapid growth of the pharmaceutical industry in emerging countries.

Asia Pacific Peptide Therapeutics CDMO Market Statical Scope

The growing pharmaceutical manufacturing activities in nations like China and India are driving the rapid growth of the Asia Pacific therapeutics CDMO market. Because of the regions skilled workforce and cost-effective production capabilities, international pharmaceutical companies are moving their outsourcing operations there. Investments in oncology drug manufacturing facilities for peptide therapeutics and biologics are growing dramatically throughout the region. Additionally, Asia Pacific CDMOs are becoming more globally competitive due to the construction of GMP-certified manufacturing facilities and the improvement of regulatory standards.

The therapeutics CDMO market in Asia Pacific is driven by cost-efficient manufacturing capabilities and rapid expansion of pharmaceutical production facilities. Governments in countries such as China, India, and South Korea are supporting domestic pharmaceutical manufacturing through favorable policies and infrastructure development. Increasing exports of active pharmaceutical ingredients and biologics are also strengthening the region's CDMO industry growth

Asia Pacific Peptide Therapeutics CDMO Market Share, By Synthesis Method, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS): Solid-phase peptide synthesis (SPPS) segment dominated the market in 2025 with a market share of 34% driven by the growing need for high purity therapeutic peptides and the growing use of automated peptide synthesis technologies. Segment dominance was further reinforced by strong pharmaceutical manufacturing capacities.
• Liquid-Phase Peptide Synthesis (LPPS): Liquid-phase peptide synthesis (LPPS) segment was the fastest growing in the market with a share of 11%, driven by the growing use of peptides in large scale manufacturing applications and the growing emphasis on their cost effective production increasing peptide research activities were another factor in the markets expansion.

Asia Pacific Peptide Therapeutics CDMO Market Share, By Service Type, 2025 (%)

• API development & manufacturing: API development & manufacturing segment dominated the market in 2025 with a market share of 20% driven by growing outsourcing from international drug manufacturers and expanding pharamceutical manufacturing capabilities. Growth was further aided by cost advantages and the availability of skilled labor.
• Process development & optimization: Process development & optimization segment was the fastest growing in the market with a market share of 11%, driven by increasing adoption of advanced manufacturing technologies and rising focus on process efficiency improvements.

Asia Pacific Peptide Therapeutics CDMO Market Share, By Peptide Type, 2025 (%)

• Generic peptide: Generic peptide segment was the fastest growing in the market with a share of 18% driven by increasing demand for affordable peptide therapeutics and expansion of generic drug manufacturing capabilities in emerging economies.
• Innovative/Novel Peptides: Innovative/novel peptide segment dominated the market in 2025 with a market share of 19% driven by an increase in clinical research activities and investments in peptide drug innovation. Demand was further increased by growing partnerships between research institutions and biotech firms.

Asia Pacific Peptide Therapeutics CDMO Market Share, By Application Area, 2025 (%)

• Oncology & Cancer Treatment: Oncology & cancer treatment segment dominated the market in 2025 with a market share of 24%, driven by the growing development of targeted peptide therapies and the rising incidence of cancer. The segment was further strengthened by government support for cancer research.
• Diabetes & Metabolic Disorders: Diabetes & metabolic disorders segment was the fastest growing in the market with a share of 15%, driven by the rapidly growing diabetic population and increasing adoption of peptide based metabolic therapies.

Asia Pacific Peptide Therapeutics CDMO Market Share, By Scale of Operation, 2025 (%)

• Research & Development Scale: Research & development scale segment was the fastest growing in the market with a share of 18%, driven by increasing peptide discovery programs and expanding investments in biotechnology innovation.
• Clinical Trial Manufacturing: Clinical trials manufacturing segment dominated the market in 2025 with a market share of 20% driven by increasing clinical research activities and growing outsourcing demand from international pharmaceutical companies.

Asia Pacific Peptide Therapeutics CDMO Market Share, By End User Type, 2025 (%)

• Large Pharmaceutical Companies: Large pharmaceutical companies segment dominated the market in 2025 with a market share of 31% driven by rising outsourcing activities and increasing peptide drug commercialization initiatives across the region.
• Biotechnology Companies: The Biotechnology companies segment was the fastest growing in the market with a share of 24%, driven by a growing startup ecosystem, increasing R&D funding, and rising peptide therapeutic innovation activities.

Competitive Landscape

The Asia Pacific therapeutics CDMO market is witnessing rapid competition due to increasing pharmaceutical outsourcing activities and cost-effective manufacturing advantages. Regional companies are expanding biologics and API manufacturing facilities to attract global pharmaceutical clients. Government support for pharmaceutical production and growing regulatory compliance standards are also strengthening market competitiveness. Major companies operating in the market include WuXi AppTec, Samsung Biologics, Syngene International, FUJIFILM Diosynth Biotechnologies, Asymchem Laboratories, and Piramal Pharma Solutions.

Segments Covered in the Report

By Synthesis Method

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid/Mixed-Phase Synthesis
• Recombinant Peptide Production
• Chemical Synthesis Methods
• Enzymatic Synthesis Approaches
• Fragment Condensation Techniques
• Convergent Synthesis Strategies

By Service Type

• API Development & Manufacturing
• Process Development & Optimization
• Analytical Method Development & Validation
• Regulatory Affairs & CMC Support
• Formulation Development
• Fill-Finish & Packaging Services
• Quality Control & Assurance
• Clinical Trial Material Manufacturing
• Commercial Manufacturing
• Technology Transfer Services

By Peptide Type

• Generic Peptides
• Innovative/Novel Peptides
• Modified Peptides (PEGylated, Lipidated)
• Cyclic Peptides
• Stapled Peptides
• Peptide-Drug Conjugates (PDCs)
• Antimicrobial Peptides
• Hormonal Peptides
• Therapeutic Proteins & Peptides
• Cosmetic & Nutraceutical Peptides

By Application Area

• Oncology & Cancer Treatment
• Diabetes & Metabolic Disorders
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Conditions
• Hormonal Therapies
• Pain Management
• Dermatology & Cosmetics
• Gastrointestinal Disorders

By Scale of Operation

• Research & Development Scale
• Clinical Trial Manufacturing
• Pilot Scale Production
• Commercial Scale Manufacturing
• Large-Scale Industrial Production
• Custom Small Batch Production

By End-User Type

• Large Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Government Research Organizations
• Clinical Research Organizations (CROs)
• Specialty Pharmaceutical Companies
• Generic Drug Manufacturers
• Cosmetic & Nutraceutical Companies